JP2010529152A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529152A5
JP2010529152A5 JP2010511525A JP2010511525A JP2010529152A5 JP 2010529152 A5 JP2010529152 A5 JP 2010529152A5 JP 2010511525 A JP2010511525 A JP 2010511525A JP 2010511525 A JP2010511525 A JP 2010511525A JP 2010529152 A5 JP2010529152 A5 JP 2010529152A5
Authority
JP
Japan
Prior art keywords
homo
cyano
androst
methylene
ene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010511525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529152A (ja
Filing date
Publication date
Priority claimed from DE102007027636A external-priority patent/DE102007027636A1/de
Application filed filed Critical
Publication of JP2010529152A publication Critical patent/JP2010529152A/ja
Publication of JP2010529152A5 publication Critical patent/JP2010529152A5/ja
Pending legal-status Critical Current

Links

JP2010511525A 2007-06-12 2008-06-04 17β−シアノ−18a−ホモ−19−ノル−アンドロスト−4−エン誘導体、その使用及び該誘導体を含む医薬 Pending JP2010529152A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007027636A DE102007027636A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
PCT/EP2008/004428 WO2008151745A1 (de) 2007-06-12 2008-06-04 17beta-cyano-18a-homo-19-nor-androst-4-en-derivat, dessen verwendung und das derivat enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
JP2010529152A JP2010529152A (ja) 2010-08-26
JP2010529152A5 true JP2010529152A5 (https=) 2011-07-21

Family

ID=38858372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010511525A Pending JP2010529152A (ja) 2007-06-12 2008-06-04 17β−シアノ−18a−ホモ−19−ノル−アンドロスト−4−エン誘導体、その使用及び該誘導体を含む医薬

Country Status (21)

Country Link
US (1) US20090048218A1 (https=)
EP (1) EP2178899B1 (https=)
JP (1) JP2010529152A (https=)
KR (1) KR20100017780A (https=)
CN (1) CN101679477A (https=)
AR (1) AR066970A1 (https=)
AU (1) AU2008261277A1 (https=)
BR (1) BRPI0813455A2 (https=)
CA (1) CA2689563A1 (https=)
CL (1) CL2008001721A1 (https=)
DE (1) DE102007027636A1 (https=)
ES (1) ES2397879T3 (https=)
IL (1) IL202300A0 (https=)
MX (1) MX2009013626A (https=)
PA (1) PA8784201A1 (https=)
PE (1) PE20090312A1 (https=)
RU (1) RU2010100334A (https=)
TW (1) TW200906846A (https=)
UY (1) UY31145A1 (https=)
WO (1) WO2008151745A1 (https=)
ZA (1) ZA201000185B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP3572417B1 (en) 2011-10-14 2025-12-17 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
HUE039057T2 (hu) 2012-12-18 2018-12-28 Univ Washington Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
IL32699A (en) * 1968-07-30 1973-06-29 American Home Prod 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them
FR2081561B1 (https=) * 1970-03-03 1973-04-06 Roussel Uclaf
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (https=) * 1971-06-01 1974-08-23 Roussel Uclaf
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
US3994937A (en) * 1972-02-11 1976-11-30 Schering Aktiengesellschaft 15α,16α-Methylene-4-estren-17β-ols
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Similar Documents

Publication Publication Date Title
JP2010529152A5 (https=)
RU2010100334A (ru) ПРОИЗВОДНОЕ 17β-ЦИАНО-18А-ГОМО-19-НОР-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, СОДЕРЖАЩИЕ ПРОИЗВОДНОЕ
JP2018530549A5 (https=)
IL272718A (en) 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
JP2009526034A5 (https=)
JP2018514593A5 (https=)
JP2016503414A5 (https=)
JP2018140982A5 (https=)
JP2008546694A5 (https=)
JP2008200039A5 (https=)
JP2019521139A5 (https=)
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
JP2009513837A5 (https=)
JP2013517299A5 (https=)
JP2008528671A5 (https=)
JP2011162556A5 (https=)
JP2011500582A5 (https=)
RU2010100331A (ru) ПРОИЗВОДНОЕ 17β-ЦИАНО-19-НОР-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, СОДЕРЖАЩИЕ УКАЗАННОЕ ПРОИЗВОДНОЕ
MX2012004848A (es) Compuestos heterociclicos triciclicos.
UA100092C2 (en) Process for the production of 3-oxo-pregnane-21,17-carbolactones and 3-oxo-pregn-4-ene-21,17-carbolactones, hemisolvate, process for the preparation thereof and process for the production of drospirenone
JP2022540421A5 (https=)
JP2014515735A5 (https=)
JP2008512426A5 (https=)
JP2010534246A5 (https=)
JP2016510765A5 (https=)